Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27464674 | 0.88 | NCF1 (0.44) | NCF1NQO1ALDH1A1HPGDF2 | |
| SCHEMBL1882121 | 0.78 | KDM4E (0.51) | ALDH1A1HPGDKDM4ESMN1; SMN2POLB | |
| SCHEMBL873205 | 0.77 | NCF1 (0.49) | NCF1NQO1ALDH1A1HPGDF2 | |
| SCHEMBL6785815 | 0.75 | PDE3B (0.38) | ALDH1A1PDE3BPDE3AKMT2ARXFP1 | |
| SCHEMBL31414248 | 0.74 | KDM4E (0.63) | NCF1NQO1ALDH1A1HPGDF2 | |
| SCHEMBL28191818 | 0.74 | ALDH1A1 (0.55) | NCF1NQO1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL874421 | 0.74 | NCF1 (0.46) | NCF1NQO1ALDH1A1HPGDF2 | |
| SCHEMBL203756 | 0.73 | NCF1 (0.57) | NCF1NQO1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7388068 | 0.72 | KDM4E (0.61) | NCF1NQO1ALDH1A1HPGDF2 | |
| SCHEMBL28247823 | 0.72 | KDM4E (0.61) | ALDH1A1HPGDF2GLAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746314-B | Containing stablizing the camptothecine compounds of 7 yuan of lactonic rings, preparation method and purposes | 华东师范大学 | 2016-07-06 | — | — | CN | disclosed |
| US-9115150-B2 | Camptothecin compound containing stable 7-membered lactone ring, preparation method and use | EAST CHINA NORMAL UNIVERSITY (CN) | 2015-08-25 | — | — | US | disclosed |
| US-20140128421-A1 | CAMPTOTHECIN COMPOUND CONTAINING STABLE 7-MEMBERED LACTONE RING, PREPARATION METHOD AND USE | EAST CHINA NORMAL UNIVERSITY (CN) | 2014-05-08 | — | — | US | disclosed |
| EP-2700642-A1 | CAMPTOTHECIN COMPOUND CONTAINING STABLE 7-MEMBERED LACTONE RING, PREPARATION METHOD AND USE | East China Normal University (CN) | 2014-02-26 | — | — | EP | disclosed |
| US-6699876-B2 | FOR CANCER THERAPY | LES LABORATOIRES SERVIER (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20030105109-A1 | For cancer therapy | LES LABORATOIRES SERVIER (FR) | 2003-06-05 | — | — | US | disclosed |
| US-6509345-B2 | For therapy of cancerous diseases | LES LABORATOIRES SERVIER (FR) | 2003-01-21 | — | — | US | disclosed |
| EP-1101765-B1 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-08-14 | — | — | EP | disclosed |
| US-20020077325-A1 | New camptothecin analogue compounds | LAVIELLE GILBERT (FR) | 2002-06-20 | — | — | US | disclosed |
| EP-1101765-A2 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105109-A1 | For cancer therapy | OXER1, OXGR1, CBR1 | NCF1 588/4885NQO1 737/4885ALDH1A1 571/4885 |
| US-20020077325-A1 | New camptothecin analogue compounds | OXER1, CBR3, CBR1 | NCF1 284/4885NQO1 444/4885ALDH1A1 1458/4885 |
| US-20140128421-A1 | CAMPTOTHECIN COMPOUND CONTAINING STABLE 7-MEMBERED LACTONE RING, PREPARATION METHOD AND USE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADCY7, CCNC | NCF1 2898/4885NQO1 773/4885ALDH1A1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.